midazolam
midazolam: 41 clinical trials tracked.
midazolam evidence translation
What we can confirm
41 tracked trials
What it means
What to watch
Prepared research question
What is verified about midazolam, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 15 study sponsors
Related indications
Clinical Trial Registry Records (41)showing 10 most recent
A 2-period Study to Evaluate the Effects of Multiple Oral Doses of MK-6916 on the Single-dose Pharmacokinetics of Midazolam and Rosuvastatin
Primary endpoint: Period 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Midazolam
A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy Participants
Primary endpoint: Plasma Concentration of Midazolam and its Metabolite
A Phase 1, Open-label, Fixed-sequence Trial in Healthy Participants to Assess the Drug Interaction Potential of BGB-43395 With A Drug Cocktail Representative for CYP3A4, CYP2C9, P-gp, and BCRP Substrates
Primary endpoint: Area Under the Concentration Time Curve from Time Zero to Infinity (AUC0-inf)
A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants
Primary endpoint: Maximum observed concentration (Cmax) of Navlimetostat
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY4355756 in Healthy Participants
Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, RELATIVE BIOAVAILABILITY, FOOD EFFECT, METABOLISM & EXCRETION, AND DRUG-DRUG INTERACTION POTENTIAL OF PF-08103402 IN HEALTHY ADULTS AND/OR ADULTS WITH MILD TO MODERATE ASTHMA
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs)
A Phase 1b, Open Label, 2-Part Study to Evaluate the Effect of Pelabresib (DAK539/CPI-0610) on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Patients With Advanced Malignancies
Primary endpoint: Maximum Plasma Concentration (Cmax) of repaglinide, midazolam, and drospirenone and ethinyl estradiol
A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants
Primary endpoint: Cohort 1: Pharmacokinetics (AUC 0-last)
A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion
Primary endpoint: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects
Primary endpoint: Number of Participants with Adverse Events (AEs)